Navigation Links
Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Today's Competitive Healthcare Market
Date:9/2/2011

CHAPEL HILL, N.C.,  Sept. 2, 2011 /PRNewswire/ -- One of the more difficult aspects of planning a new metabolic product launch is balancing the different resource and investment allocations that are needed to prepare the marketplace for a new product.  In particular, organizations wrestle with allocating the appropriate resources for informing key stakeholders as well as other critical launch activities that are carried out across different functional areas.

How does a pharma or biotech company successfully launch a new product into a crowded, competitive marketplace?

Among the several other strategies is this: Many companies seek to gain greater commercial traction in early market entry simply by investing at and above market-leader levels. 

In fact, according to "Success Factors and Failure Points in Metabolic Product Launches," a recent study from Best Practices, LLC, more than half of companies (64%) from a benchmark class of 38 top companies favor spending between 101% - 150% of the market leader's investment level during product launch.

In addition to launch spending, recent market entries have illustrated that there are a critical core set of factors for metabolic products as well as other therapeutic areas: differentiation, defining a target patient population, thought leader engagement, education of key stakeholders, demonstrating value, and use of new technologies.

"Success Factors and Failure Points in Metabolic Product Launches" explores each aspect of this framework for launch success and provides a metabolic segment as well as a data segment representing other therapeutic areas combined.  This comprehensive launch study delivers qualitative and quantitative data on differentiation, pricing, physician and thought leader education, payer and formulary access, launch readiness, resource allocation and much more.

To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr1112.htm.

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 44 managers and executives at 38 leading bio-pharma companies participated in the survey.  In-depth interviews were conducted with leaders from six organizations who have decades of experience with pharma launches.

Key topics examined in this study include:

  • Winning on Differentiated Product Positioning
  • Winning a Physician's Initial Trial of a New Product
  • Articulating Benefits that Shape Positive Market Perception
  • New Product Pricing Strategy
  • Thought Leader Engagement
  • Physician & Payer Education
  • Preparing Market Constituents
  • Winning Hospital Formulary Access
  • Resource Allocation & Timing

For more information, contact Cameron Tew, Executive Director of Research and Publishing at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

BEST PRACTICES, LLC conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Explores Utilization Trends for Prostate Cancer Treatments
2. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
3. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
4. New Study Shows Modified Citrus Pectin Activates Powerful Immune Responses
5. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
6. Comparative Study Confirms Enox Biopharmas Antimicrobial Superiority to Commercially Available Silver Coated Catheters
7. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
8. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
9. BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study
10. Study Shows That Salt Lake City Based Company Has Program That Enhances Brain Activity
11. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
Breaking Medicine News(10 mins):